16:58:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 Ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss, Norge.
2023-08-24 08:00:00
Moss, 24 August 2023

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the second quarter and first half of
2023.

Highlights

* Record sales of MNOK 34.2 in 2Q23, up 13% vs 2Q22. Revenue of MNOK 65.6 in
1H23 up 30% vs 1H22. Organic growth for the quarter was 2% in 2Q23 vs 2Q22 and
17% in 1H23 vs 1H22

* EBITDA of NOK 3.6 million in 2Q23 and NOK 3.1 million for 1H23, compared to
EBITDA of NOK -1.2 million in 2Q22 and NOK -5.4 million 1H22

* Third party product sales increased by 112% in Q2 and 68% for H1, mainly
driven by the new fCAL® turbo contracts in Sweden and Norway

* Increased use of Cystatin C recommended in updated guidelines, of which KDIGO
is the most recent one, resulting in further expansion of the global market

* Confirmed value of GCAL, validated by clinical trial, for early detection of
severe infections and prediction of clinical deterioration in an emergency
setting. In addition, the cost-saving impact of GCAL was proven in a health
economic model based on a study performed in an ICU setting

* Acquisition of Getica AB (Gothenburg, Sweden) to secure unique R&D
capabilities and to gain control of critical production competence with
estimated operational gains of approximately NOK 2.0 million from 2024

Webcast
Gentian's CEO Hilja Ibert and CFO Njaal Kind will present the results today at
10.00 am, followed by a Q&A session. Join the webcast and submit questions via
the following link:


https://attendee.gotowebinar.com/register/6319884417978803549

The webcast will be available on the company website after the presentation and
will be hosted by Hilja Ibert, CEO and Njaal Kind, CFO.

IR contact:

Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 24 August 2023 at 08:00 CET.


About Gentian
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.